Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.5.4 is now shown on the page, replacing the previous v3.5.3. This reflects an updated revision of the study record.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThis updates the ClinicalTrials.gov page’s revision/version indicator from v3.5.2 to v3.5.3, reflecting a platform release rather than a change to the underlying study information.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check60 days agoChange DetectedResults posted with expanded outcome measures (ORR, TTR, Recurrence Free Survival, OS) and biomarker analyses, plus related study documents.SummaryDifference2%

- Check67 days agoChange DetectedMeSH terms now include Hepatocellular carcinoma (HCC) and a link to the Genetic and Rare Diseases Information Center; the page footer shows Revision: v3.5.0, replacing v3.4.3.SummaryDifference0.2%

- Check74 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.